“So, one can say (statistically speaking): I don't have enough information therefore I will not invest.”

This is pretty much the argument I see so often on other message boards, where the poster (correctly) points out that our data is “anecdotal”.

And my response is always the same: you can wait for statistically significant data before investing, but by then it will already be priced in (along with whatever other good news is anticipated at that time).

When the data finally proves what Leronlimab is really capable of (for better or worse), this will no longer be a $3 stock.